JP5619352B2 - 細菌を処置するための組成物および方法 - Google Patents

細菌を処置するための組成物および方法 Download PDF

Info

Publication number
JP5619352B2
JP5619352B2 JP2008524245A JP2008524245A JP5619352B2 JP 5619352 B2 JP5619352 B2 JP 5619352B2 JP 2008524245 A JP2008524245 A JP 2008524245A JP 2008524245 A JP2008524245 A JP 2008524245A JP 5619352 B2 JP5619352 B2 JP 5619352B2
Authority
JP
Japan
Prior art keywords
nisin
mupirocin
bacteria
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008524245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502965A (ja
JP2009502965A5 (cg-RX-API-DMAC10.html
Inventor
スコット マイケル ウォルシュ
スコット マイケル ウォルシュ
キャサリン ピッタウェイメアリー
メアリー キャサリン ピッタウェイ
ジェイムズ ジェイ． モンド
ジェイムズ ジェイ． モンド
Original Assignee
バイオシネクサス インコーポレーティッド
バイオシネクサス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオシネクサス インコーポレーティッド, バイオシネクサス インコーポレーティッド filed Critical バイオシネクサス インコーポレーティッド
Publication of JP2009502965A publication Critical patent/JP2009502965A/ja
Publication of JP2009502965A5 publication Critical patent/JP2009502965A5/ja
Application granted granted Critical
Publication of JP5619352B2 publication Critical patent/JP5619352B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2008524245A 2005-07-28 2006-07-28 細菌を処置するための組成物および方法 Expired - Fee Related JP5619352B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70301005P 2005-07-28 2005-07-28
US60/703,010 2005-07-28
US72519305P 2005-10-11 2005-10-11
US60/725,193 2005-10-11
US77903406P 2006-03-03 2006-03-03
US60/779,034 2006-03-03
PCT/US2006/029672 WO2007014372A2 (en) 2005-07-28 2006-07-28 Compositions and methods for treating bacteria

Publications (3)

Publication Number Publication Date
JP2009502965A JP2009502965A (ja) 2009-01-29
JP2009502965A5 JP2009502965A5 (cg-RX-API-DMAC10.html) 2012-07-26
JP5619352B2 true JP5619352B2 (ja) 2014-11-05

Family

ID=37684026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524245A Expired - Fee Related JP5619352B2 (ja) 2005-07-28 2006-07-28 細菌を処置するための組成物および方法

Country Status (6)

Country Link
US (2) US7517852B2 (cg-RX-API-DMAC10.html)
EP (1) EP1940437B1 (cg-RX-API-DMAC10.html)
JP (1) JP5619352B2 (cg-RX-API-DMAC10.html)
CA (1) CA2617133C (cg-RX-API-DMAC10.html)
ES (1) ES2436614T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007014372A2 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617133C (en) * 2005-07-28 2014-09-30 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections
US9115358B2 (en) 2006-08-11 2015-08-25 President And Fellows Of Harvard College Moenomycin biosynthesis-related compositions and methods of use thereof
WO2009032470A2 (en) * 2007-08-22 2009-03-12 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant staphylococcus aureus
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College MOENOMYCIN ANALOGUE, SYNTHESIS PROCESS AND USE
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
JP5374260B2 (ja) * 2009-07-10 2013-12-25 静岡商工会議所 農業用資材
CN103189046B (zh) 2010-09-09 2016-09-07 玫琳凯有限公司 包含植物提取物的局部护肤制剂
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
WO2012125941A1 (en) * 2011-03-17 2012-09-20 Follica, Inc. Lithium treatment for microbial infections
TW201334696A (zh) * 2012-02-28 2013-09-01 Marrone Bio Innovations Inc 以假單胞菌防治植物病原微生物之方法與取自假單胞菌之物質及組成物
WO2013152279A1 (en) 2012-04-06 2013-10-10 President And Fellows Of Harvard College Chemoenzymatic methods for synthesizing moenomycin analogs
US10106833B2 (en) 2012-04-06 2018-10-23 President And Fellows Of Harvard College Methods and compounds for identifying glycosyltransferase inhibitors
US9273084B2 (en) 2012-04-06 2016-03-01 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
WO2016044443A1 (en) * 2014-09-16 2016-03-24 Philip Demokritou Engineered water nanostructures (ewns) and uses thereof
US10617703B2 (en) * 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12502370B2 (en) * 2019-04-11 2025-12-23 Cmpd Licensing, Llc Wound treatments and compositions
EP3331496B1 (en) * 2015-08-05 2021-01-27 The University of Rochester Antimicrobial compositions comprising mupirocin and neomycin
AU2017240064B8 (en) 2016-03-31 2021-11-11 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
JP2019510037A (ja) 2016-03-31 2019-04-11 ゴジョ・インダストリーズ・インコーポレイテッド 抗菌ペプチド刺激性洗浄組成物
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2018098152A1 (en) 2016-11-23 2018-05-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2019081309A1 (en) 2017-10-27 2019-05-02 OCE Holding B.V. MULTI-ROLL PRINTER CONTROL DEVICE, PRINTING SYSTEM, AND MULTI-ROLL PRINTER CONTROL METHOD
CA3128389A1 (en) * 2019-03-08 2020-09-17 Fraunhofer Usa, Inc. Novel antimicrobial lantibiotic peptide and uses thereof
US12156875B2 (en) * 2019-04-11 2024-12-03 Cmpd Licensing, Llc Wound treatments and compositions
CN114340605A (zh) * 2019-08-26 2022-04-12 肯特州立大学 合理设计的指甲花醌衍生物作为耐多药金黄色葡萄球菌的抗菌剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135910A (en) * 1988-06-22 1992-08-04 The Public Health Research Institute Of The City Of New York Nisin compositions for use as enhanced, broad range bactericides
US5260271A (en) 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
WO1992018633A1 (en) * 1991-04-11 1992-10-29 Stichting Nederlands Instituut Voor Zuivelonderzoek (Nizo) Lantibiotics similar to nisin a, lactic acid bacteria which produce such lantibiotics, method for constructing such lactic acid bacteria and method for preserving foodstuffs with the aid of these lantibiotics and these lactic acid bacteria producing lantibiotics
CA2169847C (en) 1993-08-20 2006-02-14 John Edmondson Peel Method for the prevention and treatment of bovine mastitis
GB9423404D0 (en) * 1994-11-19 1995-01-11 Biotech & Biolog Scien Res Production of nisin
US5866539A (en) 1995-06-23 1999-02-02 Ambi Inc. Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
US5928146A (en) * 1996-03-15 1999-07-27 Hitachi Medical Corporation Inspection apparatus using nuclear magnetic resonance
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
CO4910145A1 (es) * 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
IL123143A (en) * 1998-02-02 2001-08-26 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
US20060140984A1 (en) * 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
BR0316776A (pt) * 2002-12-10 2005-10-25 Biosynexus Inc Formula para anti-infeccioso tópico
CA2617133C (en) * 2005-07-28 2014-09-30 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections

Also Published As

Publication number Publication date
CA2617133A1 (en) 2007-02-01
EP1940437A4 (en) 2009-08-19
US20090196945A1 (en) 2009-08-06
US20070060506A1 (en) 2007-03-15
JP2009502965A (ja) 2009-01-29
EP1940437A2 (en) 2008-07-09
CA2617133C (en) 2014-09-30
US8697639B2 (en) 2014-04-15
WO2007014372A2 (en) 2007-02-01
EP1940437B1 (en) 2013-09-04
ES2436614T3 (es) 2014-01-03
WO2007014372A3 (en) 2007-07-26
US7517852B2 (en) 2009-04-14

Similar Documents

Publication Publication Date Title
US8697639B2 (en) Compositions and methods for treating bacteria
US20090304783A1 (en) Compositions and methods for treating bacteria
RU2607660C2 (ru) Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент
Hidalgo et al. Infections in critically ill burn patients
EP1330221B1 (en) Medical compositions and dressings treating microbial infections of skin lesions
JP7118022B2 (ja) 細菌性バイオフィルムを除去するためのセアプローゼの使用
US9173972B2 (en) Methods and compositions for promoting wound healing
Weber et al. Antibiotic prophylaxis in clean-contaminated head and neck oncologic surgery
O'Reilly et al. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin
CN101175531A (zh) 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物
US20210260101A1 (en) Potentiated antibiotic compositions and methods of use for treating bacterial infections and biofilms
EP1200463B1 (en) Antimicrobial histone h1 compositions and methods of use thereof
Pawar et al. Comparison of in vitro antibacterial activity of streptomycin-diclofenac loaded composite biomaterial dressings with commercial silver based antimicrobial wound dressings
Pachón-Ibáñez et al. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin
MX2012010013A (es) Composiciones para administracion topica.
Nakhla et al. Microbiological aspects of burns at Mount Vernon Hospital, UK
WO2007092582A2 (en) Neutralization of bacterial spores
Yasim et al. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat
CN118251216A (zh) 用于生物膜破坏的方法
WO2017019943A1 (en) Antimicrobial formulations and applications thereof
US20260130862A1 (en) Antimicrobial compositions and methods of use thereof
Gardam et al. Disinfectants and Antiseptics
Shankar et al. Newer antibiotics
van Saene et al. A Possible Explanation for the Success of SDD
Bébéar Pre-clinical Microbiology—Atypical Organisms

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120607

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140917

R150 Certificate of patent or registration of utility model

Ref document number: 5619352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees